Optimum chemotherapy for the management of advanced biliary tract cancer - Wikidata - wikimedia - TriplyDB

Optimum chemotherapy for the management of advanced biliary tract cancer

Optimum chemotherapy for the management of advanced biliary tract cancer

http://www.wikidata.org/entity/Q27010873

about

Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis.Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing.Effect of midkine on gemcitabine resistance in biliary tract cancer.

P2860

Q33436600-AC2BA598-4BAC-438E-AFEB-43BDF73B2640 Q36870198-95E6CDC4-3196-49DC-8492-C1ED2EE0426B Q48532998-8702A886-2AA4-43AF-AF01-4117A7E6BE76

P2860

Optimum chemotherapy for the management of advanced biliary tract cancer

http://www.wikidata.org/entity/Q27010873

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Optimum chemotherapy for the management of advanced biliary tract cancer

@ast

Optimum chemotherapy for the management of advanced biliary tract cancer

@en

Optimum chemotherapy for the management of advanced biliary tract cancer

@nl

type

label

Optimum chemotherapy for the management of advanced biliary tract cancer

@ast

Optimum chemotherapy for the management of advanced biliary tract cancer

@en

Optimum chemotherapy for the management of advanced biliary tract cancer

@nl

prefLabel

Optimum chemotherapy for the management of advanced biliary tract cancer

@ast

Optimum chemotherapy for the management of advanced biliary tract cancer

@en

Optimum chemotherapy for the management of advanced biliary tract cancer

@nl

P1433

Q27010873-81BFF43E-AC9C-477B-84F2-3B6364576B29

P1476

Q27010873-E506ECC1-EEC0-47E9-A426-65936FFEC7CA

P2093

Q27010873-6AB25F6D-88B7-499C-9895-B6C5B2C5DC10

P2860

Q27010873-047C8719-2B43-4077-91EC-E6E8E9E31A5D

Q27010873-06EF598C-C0D5-4655-BB41-FAAF48632F8A

Q27010873-0D89A226-240F-447E-84FC-B618FE2F6730

Q27010873-0EAE3552-8A0B-4BCB-B09E-54662691ED95

Q27010873-10F2B2D1-275C-44FE-ADF4-50B77248192E

Q27010873-163D5C74-CB83-4DC5-A2E1-F73470CC71F1

Q27010873-1D6E1D00-0BDD-4EFC-83E0-597AB06DC3D2

Q27010873-1D916D99-9044-4D77-A82A-0CFAAD049DA7

Q27010873-20F751B9-DDCF-4188-BA13-DA7B452A1C6E

Q27010873-21A62565-8146-4147-A290-ED0A41A331AF

P304

Q27010873-83A772F5-A148-412C-99CD-9CE9E75C9734

P31

Q27010873-35811832-C0F3-40CC-8F69-A7620F567ED3

P3181

Q27010873-BCE68648-B085-497F-B209-1D3A3CC1FF79

P356

Q27010873-99EFA1F9-D9FA-45BF-B852-7FD41D8A12CA

P407

Q27010873-A1D7EE12-1DEC-4C34-913F-AE85B61528DD

P433

Q27010873-833ED39A-090F-4CC5-A41B-FDE815AC6A28

P478

Q27010873-8DBAB802-7A10-49E9-BB0C-32174EDCB43E

P577

Q27010873-62E7590C-01D3-4486-B8B5-9484993B27CC

P5875

Q27010873-58941C82-773E-44A3-A234-88A2DB08DF3E

P698

Q27010873-692232C4-CB8E-45B6-BF9A-F2E56D0AAF5F

P921

Q27010873-58E42B81-7AFB-4F21-A575-4E03DBCD9391

P932

Q27010873-4A964DD0-94C1-483E-96C4-A7E4A57A72BF

P3181

P356

WJG.V21.I14.4121

P1433

World Journal of Gastroenterology

P1476

Optimum chemotherapy for the management of advanced biliary tract cancer

@en

P2093

Marwan Ghosn

http://www.w3.org/2001/XMLSchema#string

P2860

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.

Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

Biliary tract cancers.

Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1.

Phase II study of erlotinib in patients with advanced biliary cancer.

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

P304

4121-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2131138

http://www.w3.org/2001/XMLSchema#string

P356

10.3748/WJG.V21.I14.4121

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275217489

http://www.w3.org/2001/XMLSchema#string

P698

25892861

http://www.w3.org/2001/XMLSchema#string

P921

P932

4394072

http://www.w3.org/2001/XMLSchema#string